All News Skye Bioscience, Inc.

Equities

EMBI

US83086J2006

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
12.05 ^USD	-1.63%		+6.45%	+343.01%

10/05	Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
23/04	Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting	13/05	AQ
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	11/05	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index	23/04	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index	12/04	CI
Skye Bioscience Uplists to The Nasdaq Global Market	10/04	AQ
SKYE BIOSCIENCE : AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS - Form 8-K	04/04	PU
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
Piper Sandler Adjusts Skye Bioscience Price Target to $20 From $12, Maintains Overweight Rating	14/03	MT
Skye Bioscience, Inc. announced that it has received $40 million in funding	13/03	CI
Skye Bioscience Announces $40 Million Private Placement Equity Financing	11/03	NE
Skye Bioscience, Inc. announced that it expects to receive $40 million in funding	11/03	CI
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors	04/03	AQ
Skye Bioscience Announces Board Changes	04/03	CI
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	26/02	AQ
Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	26/02	CI
Skye Bioscience, Inc. announced that it has received $49.99101 million in funding	12/02	CI
Skye Bioscience to Present at Oppenheimer Investor Conference	07/02	NE
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing	29/01	NE
Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding	29/01	CI
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease	09/01	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Skye Bioscience, Inc.

Equities

EMBI

US83086J2006

All News

Filters